Tuesday, September 24, 2013


"The U.S. Food and Drug Administration has granted breakthrough therapy designation to volasertib for the treatment of patients with previously untreated acute myeloid leukemia who are ineligible for intensive remission induction therapy, and who are 65 or older. Volasertib is an investigational inhibitor of polo-like kinase (Plk)." from Oncology time.  go to full article

*Kathy Miller from Indiana University suggests that the best adjuvant chemotherapy in relevent Breast cancer patient is AC Q3weeks followed by weekly Paclitaxel as it has comparative efficacy and better tolerance of the weekly Taxol part!
Post a Comment